Under the auspices of the Advance Market Commitment (AMC), an innovative program by Gavi, the Vaccine Alliance, Pfizer has pledged to supply up to 930 million doses to infants and young children in Gavi-eligible countries through 2027.

The AMC is a public-private health funding program designed to create a sustainable marketplace, provide an affordable and stable supply of certain vaccines at a steeply discounted price, and stimulate the development and expansion of manufacturing capacity for vaccines specifically for the developing countries.

Pfizer was proud to have a vaccine included in the childhood immunization program of a developing country within one year of introduction in the United States and European Union - a historic precedent given the average 10-15 year lag for introducing newer vaccines into developing countries following their introduction in industrialized nations.

A key component of Pfizer's commitment to make true inroads toward global healthcare access is to work through private-public partnerships such as the AMC which are vital to accelerating the availability of affordable vaccines to those children who are most vulnerable.